Gruenenthal Presents Phase III Qutenza Results in Post-Surgical Neuropathic Pain
Gruenenthal presented late-breaking Phase III RISE trial data for Qutenza at the IASP 2026 World Congress on Pain.
Related stories
Hershey Reports Third-Quarter 2026 Revenue of $3.28 Billion, EPS of $2.88
Hershey said revenue rose 3% year over year to $3.28 billion, net income increased to $581 million and diluted EPS rose to $2.88. Higher pricing and the LesserEvil acquisition supp
M impact | EQUITY | Oct 29, 2026, 05:51 PM UTC
Scotiabank Cuts Oracle Price Target to $205 From $215
Scotiabank kept its Sector Outperform rating after Oracle's investor day. Oracle shares fell about 3% in morning trading.
M impact | EQUITY | Oct 29, 2026, 05:51 PM UTC
Horizon Industrial Parks Q2 Revenue Grows 30%
Horizon Industrial Parks reported 2.5 million sq. ft. of warehouse leasing in the September quarter and said it turned a profit. The company described demand as robust.
M impact | EQUITY | Oct 29, 2026, 05:51 PM UTC
Coal India Reports 57% Annual Profit Growth, Declares Interim Dividend
Coal India said consolidated net profit rose 57% year over year in the second quarter of FY2026-27. Its board also announced a second interim dividend for FY27.
M impact | EQUITY | Oct 29, 2026, 05:51 PM UTC
Hindustan Unilever Shares on Track for Worst Annual Performance in 22 Years
Hindustan Unilever shares were on track for their worst annual performance in over two decades, as investors stayed away from consumer goods stocks amid a challenging sector outloo
M impact | EQUITY | Oct 29, 2026, 05:51 PM UTC
Howmet Aerospace Shares Rise 5.48% to $205.90
Shares rose 5.48% to $205.90 at 11:45 a.m. ET on October 29. The report cites 45% year-over-year growth in gas-turbine revenue and expanded repurchase authorization.
M impact | EQUITY | Oct 29, 2026, 05:46 PM UTC